Clinical trial Recruiting at 625 sites Phase 3 Interventional Ages 18 to 130

Evaluating Balcinrenone and Dapagliflozin for Heart Failure with Kidney Issues

Official title: A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared With Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients With Heart Failure and Impaired Kidney Function

Run by AstraZeneca · NCT06307652 · Data updated 2026-11-12

This study is testing if a combination of two medications, balcinrenone and dapagliflozin, can help people with heart failure and kidney problems feel better compared to taking dapagliflozin alone.

Research outlook What's coming for Heart failure: the next 6 months to 5 years

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 130 Years
SexAll
Enrollment3850 (estimated)
SponsorAstraZeneca
Industry-sponsored
Locations852 sites (Alexander City, Alabama and 851 other locations)
StatusRecruiting
StartedApril 12, 2024
Main results expectedApril 16, 2027
Study endsApril 16, 2027
Registry record updatedOctober 13, 2026
Trial IDNCT06307652 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older with symptomatic heart failure, recent heart failure events, and impaired kidney function.

Probably not a fit

Patients with acute coronary syndrome, recent major cardiac surgeries, or specific heart conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase III clinical trial investigates the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients suffering from chronic heart failure and impaired kidney function. Participants will be randomly assigned to receive one of three treatment regimens, including varying doses of balcinrenone/dapagliflozin or dapagliflozin with matching placebos. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events over an average duration of 22 months. Conducted across approximately 700 sites in 40 countries, this trial seeks to provide insights into effective management strategies for patients with these conditions.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment options for patients with heart failure and impaired kidney function, potentially reducing cardiovascular deaths and heart failure events.

How similar studies have gone: Other studies have shown promise in treating heart failure with similar approaches, but this specific combination is being evaluated for the first time.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 18 years
* Documented diagnosis of symptomatic HF (NYHA functional class II-IV)
* Having had a recent HF event within 6 months (hospitalization or urgent visit)
* Have a LVEF value from an assessment within the last 12 months
* Managed with SoC therapy for HF and renal impairment according to local guidelines
* NT-proBNP must be \>300 pg/mL (\>600 pg/mL if concomitant atrial fibrillation or atrial flutter)
* Not taking an MRA
* An eGFR ≥ 20 to \< 60 mL/min/1.73 m2
* Serum/plasma potassium ≤ 5.0 mmol/L

Exclusion Criteria:

* Acute coronary syndrome (unstable angina or myocardial infarction), stroke or transient ischaemic attack within the previous 3 months prior to enrolment or during the screening period
* Major cardiac surgery, coronary revascularisation or valvular repair or replacement, or implantation of a Cardiac resynchronisation therapy device within 3 months prior to enrolment or during the screening period, or planned to undergo any of these operations
* History of hypertrophic obstructive cardiomyopathy
* Complex congenital heart disease or severe uncorrected primary valvular disease
* Symptomatic bradycardia or second- or third-degree heart block without a pacemaker
* Systolic BP \< 90 mmHg, or symptomatic hypotension within the past 24 hours
* Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD or exacerbation of COPD requiring invasive mechanical ventilation assistance within 12 months prior to enrolment
* Type 1 diabetes mellitus
* Kidney replacement therapy in the past 4 weeks, currently requiring kidney replacement or imminent plan to start kidney replacement therapy
* Acute or chronic liver disease with severe impairment of liver function, eg, ascites, oesophageal varices, coagulopathy, and encephalopathy
* Suspected or confirmed COVID-19 infection within the last 4 weeks or hospitalisation for COVID-19 within the last 12 weeks
* Treatment with strong or moderate CYP3A4 inhibitor or inducer

Where it's running

  • Research Site
    Alexander City, Alabama, United States
    Recruiting
  • Research Site
    Fairhope, Alabama, United States
    Recruiting
  • Research Site
    Huntsville, Alabama, United States
    Recruiting
  • Research Site
    Phoenix, Arizona, United States
    Recruiting
  • Research Site
    Phoenix, Arizona, United States
    Recruiting
  • Research Site
    Little Rock, Arkansas, United States
    Recruiting
Show 44 more locations
  • Research Site
    Beverly Hills, California, United States
    Recruiting
  • Research Site
    Covina, California, United States
    Recruiting
  • Research Site
    Los Angeles, California, United States
    Recruiting
  • Research Site
    Los Angeles, California, United States
    Recruiting
  • Research Site
    Redding, California, United States
    Recruiting
  • Research Site
    San Diego, California, United States
    Recruiting
  • Research Site
    San Francisco, California, United States
    Recruiting
  • Research Site
    Vista, California, United States
    Recruiting
  • Research Site
    West Hills, California, United States
    Recruiting
  • Research Site
    Aurora, Colorado, United States
    Recruiting
  • Research Site
    Boca Raton, Florida, United States
    Recruiting
  • Research Site
    Bradenton, Florida, United States
    Recruiting
  • Research Site
    Delray Beach, Florida, United States
    Recruiting
  • Research Site
    Fort Lauderdale, Florida, United States
    Recruiting
  • Research Site
    Gainesville, Florida, United States
    Recruiting
  • Research Site
    Jacksonville, Florida, United States
    Recruiting
  • Research Site
    Miami, Florida, United States
    Recruiting
  • Research Site
    Miami Lakes, Florida, United States
    Recruiting
  • Research Site
    Palm Beach Gardens, Florida, United States
    Recruiting
  • Research Site
    Pensacola, Florida, United States
    Recruiting
  • Research Site
    Safety Harbor, Florida, United States
    Recruiting
  • Research Site
    Saint Augustine, Florida, United States
    Recruiting
  • Research Site
    St. Petersburg, Florida, United States
    Recruiting
  • Research Site
    Tampa, Florida, United States
    Recruiting
  • Research Site
    Atlanta, Georgia, United States
    Recruiting
  • Research Site
    Peachtree City, Georgia, United States
    Recruiting
  • Research Site
    Tucker, Georgia, United States
    Recruiting
  • Research Site
    Chicago, Illinois, United States
    Recruiting
  • Research Site
    Hazel Crest, Illinois, United States
    Recruiting
  • Research Site
    Peoria, Illinois, United States
    Recruiting
  • Research Site
    Winfield, Illinois, United States
    Recruiting
  • Research Site
    Elkhart, Indiana, United States
    Recruiting
  • Research Site
    Evansville, Indiana, United States
    Recruiting
  • Research Site
    Muncie, Indiana, United States
    Recruiting
  • Research Site
    Munster, Indiana, United States
    Recruiting
  • Research Site
    Waterloo, Iowa, United States
    Recruiting
  • Research Site
    Wichita, Kansas, United States
    Recruiting
  • Research Site
    West Monroe, Louisiana, United States
    Recruiting
  • Research Site
    Rockville, Maryland, United States
    Recruiting
  • Research Site
    Boston, Massachusetts, United States
    Recruiting
  • Research Site
    Bloomfield Hills, Michigan, United States
    Recruiting
  • Research Site
    Ypsilanti, Michigan, United States
    Recruiting
  • Research Site
    Saint Paul, Minnesota, United States
    Recruiting
  • Research Site
    Jackson, Mississippi, United States
    Recruiting

+802 more sites. See ClinicalTrials.gov for the full list.

Study contacts

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.